Outcomes for adults with KMT2A-r acute myeloid leukemia treated with venetoclax plus azacitidine (Ven/Aza) or intensive chemotherapy (IC): A single-center retrospective study.

Authors: Amritpal Singh, Grace Bosma, Jingjing Zhang, Diana Abbott, Maria Amaya, Andrew Kent, Mathew Angelos, Marc Schwartz, Jonathan Aaron Gutman, Daniel Aaron Pollyea, Christine McMahon

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.e18537

Source: Full article

---

Abstract

e18537